Year None202320222021202020192018 Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics Feb 21, 2023 Read More Sensei Biotherapeutics to Participate in Citi’s 2023 Virtual Oncology Leadership Summit Feb 16, 2023 Read More Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics Feb 14, 2023 Read More Sensei Biotherapeutics Signs Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to Expand Development Plan for SNS-101, a Conditionally Active VISTA-blocking Antibody Feb 06, 2023 Read More Sensei Biotherapeutics Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating SNS-101, a Conditionally Active VISTA-blocking Antibody, in Combination with Libtayo® (cemiplimab) in Solid Tumors Jan 05, 2023 Read More Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Displaying 11 - 15 of 15
